Atopic March
Introduction
The atopic march, also known as the allergic march, describes a common developmental progression of allergic diseases often observed in children with IgE-antibody responses to environmental allergens (atopy). [1] This sequential manifestation typically begins in infancy with atopic dermatitis (eczema), followed by the development of other allergic conditions such as food allergy, asthma, and/or allergic rhinitis later in childhood. [1] While this is the most frequently observed pattern, individuals can experience variations in the order of disease onset, skip certain manifestations, or halt progression entirely. [1] Approximately 20-30% of infants with eczema will follow this trajectory, which is often associated with more severe and persistent allergic disease. [2]
Biological Basis
The underlying biological mechanisms of the atopic march involve a complex interplay of genetic and environmental factors. A significant breakthrough in understanding this progression was the discovery of loss-of-function mutations in the FLG (filaggrin) gene, which provides genetic evidence linking skin barrier dysfunction to eczema and subsequent asthma development. [2] FLG variants are recognized as a major predisposing factor for atopic dermatitis and allergic disease. [3] Research indicates a largely shared genetic architecture across atopic diseases, with many identified atopic dermatitis loci overlapping with those involved in the atopic march. [4] Genome-wide association studies (GWAS) have identified several susceptibility loci involved in the atopic march, including novel associations with genes like EFHC1 on chromosome 6p12.3 and between TMTC2 and SLC6A15 on chromosome 12q21.3. [2] For instance, the single nucleotide polymorphism rs9357733 in the region containing PAQR8, EFHC1, and TRAM2 has been associated with the atopic march. [2] Another variant, rs993226, has also been linked to this progression. [2] The involvement of genes like EFHC1, which is expressed in the mucociliary epithelium, highlights the importance of barrier function beyond the skin in defending against allergens. [2]
Clinical Relevance
The atopic march is clinically relevant due to its association with severe and persistent allergic disease manifestations. [2] Early onset atopic dermatitis, particularly with increased severity, is a significant risk factor for the development of food sensitization and subsequent allergic conditions. [5] Understanding the trajectory of the atopic march allows healthcare providers to identify at-risk individuals and potentially intervene early to prevent or mitigate the progression of allergic diseases. For example, eosinophilic esophagitis has been identified as a late manifestation of the allergic march. [6] The progression of atopic dermatitis to respiratory allergies like asthma and allergic rhinitis is a well-established link. [7] Recognizing these patterns can guide diagnostic strategies and management approaches, potentially leading to better patient outcomes.
Social Importance
The atopic march has considerable social importance due to the significant burden allergic diseases place on individuals, families, and public health systems. The chronic nature and sequential development of conditions like atopic dermatitis, food allergy, asthma, and allergic rhinitis can severely impact quality of life, necessitate ongoing medical care, and result in substantial economic costs. [8] Furthermore, health disparities related to allergic manifestations have been observed, underscoring the need for equitable access to care and preventive strategies. [1] Continued research into the genetic and environmental factors influencing these distinct allergic trajectories is crucial for refining phenotype definitions, expanding diverse GWAS cohorts, and ultimately developing targeted prevention and treatment strategies to alleviate the global burden of allergic diseases. [4]
Methodological and Statistical Considerations
Research into the atopic march often encounters limitations rooted in study design and statistical power. Many studies are secondary analyses of health records from single institutions, which can introduce inherent biases and restrict the broader applicability of findings. [1] Furthermore, the selection criteria for study populations may lead to biases, such as an overrepresentation of individuals initially recruited for eczema or asthma, potentially skewing the discovery of genetic loci towards these specific conditions rather than the broader atopic march phenotype. [2] Such methodological choices can inadvertently inflate effect sizes or contribute to an incomplete understanding of the genetic architecture that underlies the progression of atopic diseases.
A lack of sufficient statistical power represents another critical limitation, particularly in detecting subtle genetic effects or specific patterns of disease progression. For example, some analyses may not have the power to precisely identify the effect of certain loci on the progression from eczema to asthma, even when prior evidence suggests such links. [2] This issue is compounded by challenges in replicating findings across diverse cohorts, where factors like low allele frequencies or variations in study methodologies can lead to replication failures, thereby questioning the robustness of identified genetic associations. [9] Additionally, variations in patient follow-up times within cohorts can influence association results, introducing further variability and uncertainty into the interpretation of longitudinal data. [1]
Phenotypic Definition and Measurement Challenges
A significant limitation in atopic march research pertains to the consistency and accuracy of phenotypic definitions and measurements. Many studies rely on diagnostic codes extracted from routine clinical care, which can be influenced by billing or administrative factors, potentially introducing biases into the collected data. [1] While efforts are made to validate these codes against accepted practice parameters, the inherent variability can result in misclassification bias, especially when comprehensive asthma status or other atopic condition data are not uniformly available across all cohorts. [10] Such misclassification can diminish statistical power and obscure true genetic associations with the complex atopic march phenotype.
The intricate nature of defining the atopic march, which involves the sequential development of multiple allergic conditions, adds to these measurement challenges. Accurately distinguishing between "eczema alone," "asthma alone," and the full "atopic march" phenotype necessitates rigorous and often longitudinal data, which are not consistently available across all research populations. [2] Moreover, the absence of genome-wide significant loci in sex-stratified analyses in some studies suggests that potential sex-specific genetic contributions to allergic trajectories might be under-investigated or require larger, more finely resolved datasets for detection. [1]
Ancestry and Generalizability Issues
A critical limitation in understanding the atopic march is the lack of diversity in study populations, which often hinders the generalizability of research findings. A substantial portion of genetic studies, particularly genome-wide association studies (GWAS), has predominantly focused on populations of European ancestry. [4] This narrow focus means that genetic loci not captured by European ancestry meta-analyses, or those with different allele frequencies and effect sizes in other ancestral groups, may be overlooked, thereby limiting the applicability of findings to a global population. [4]
Significant ancestral genetic differences exist, with certain single nucleotide polymorphisms (SNPs) being more common in individuals of African ancestry compared to European ancestry, and vice versa. [1] These disparities highlight the potential for different genetic drivers of allergic trajectories across populations, underscoring the need for further research to understand their relative contributions and to address health disparities. [1] Furthermore, the reliance on assigned rather than self-identified racial or ancestral groups in some studies can introduce additional biases and confounders, impacting the accuracy of ancestry-specific analyses and the broader generalizability of findings. [1]
Unexplained Heritability and Gene–Environment Complexity
Despite considerable advancements, a substantial portion of the heritability of atopic diseases, including the atopic march, remains unexplained, indicating limitations in current genetic models. This "missing heritability" may be attributed to several factors, such as genetic loci not fully captured by common variant genotyping arrays, including rare variants with potentially large effect sizes. [4] The intricate interplay of complex gene-gene and gene-environment interactions is also believed to play a crucial role in the genetic architecture of atopic dermatitis and the atopic march, yet these interactions are often challenging to comprehensively model and assess within current study designs. [4]
Environmental factors are recognized as important contributors to atopic diseases, but their precise role as confounders or modifiers in the context of genetic susceptibility to the atopic march is still being fully elucidated. Current research often lacks robust longitudinal data that comprehensively capture environmental exposures alongside genetic profiles, making it difficult to disentangle their individual and interactive effects on disease progression. [2] Understanding these complex relationships is essential to move beyond merely identifying associated loci to uncovering the underlying molecular mechanisms and developing targeted preventive or therapeutic strategies.
Variants
Genetic variations play a crucial role in predisposing individuals to the atopic march, a common progression where eczema in infancy is followed by asthma and/or allergic rhinitis in childhood. A multi-stage genome-wide association study (GWAS) has identified several susceptibility loci linked to this specific phenotype. Among these, rs9357733 located in the EFHC1 gene on chromosome 6p12.3 and rs993226 situated between TMTC2 and SLC6A15 on chromosome 12q21.3 were identified as novel loci specifically associated with the combined eczema and asthma phenotype, marking their first association with allergic disease. [2] The EFHC1 gene, encoding EF-hand domain (C-terminal)-containing protein 1, is ubiquitously expressed and its variants have been implicated in conditions like juvenile epilepsy, with experimental evidence suggesting its role in cilia function, which is critical for mucociliary defense in the respiratory tract against pathogens and allergens. [2] Similarly, rs993226 is near SLC6A15, which encodes a sodium/chloride-dependent membrane transporter for neutral amino acids, BAT2, a protein predominantly expressed in respiratory tract cells, indicating a potential impact on respiratory health and allergic airway disease development. [2]
Other significant variants contribute to the genetic landscape of the atopic march by influencing immune regulation and barrier function. The variant rs479844 is located within the AP5B1-OVOL1 region on chromosome 11q13.1. OVOL1 (Ovo-like transcriptional repressor 1) is a transcription factor known to be involved in epithelial differentiation and maintaining skin barrier integrity, a key factor in eczema pathogenesis and subsequent allergic sensitization. [2] The rs17690965 variant is found in the IL4/KIF3A region on 5q31.1. IL4 (Interleukin 4) is a central cytokine in allergic inflammation, driving the immune response towards a Th2 phenotype characteristic of allergic diseases, while KIF3A (kinesin family member 3A) plays a role in intracellular transport and cilia formation, potentially affecting immune cell function and barrier integrity. [2] Additionally, rs10445308 in the IKZF3 gene on 17q21 is relevant; IKZF3 (IKAROS family zinc finger 3) is a transcription factor vital for lymphocyte development and function, influencing the differentiation of immune cells and their roles in allergic responses. [2]
Several other variants also contribute to the complex genetics of the atopic march, often through their roles in gene regulation or immune cell function. These include rs2155219 in the EMSY-LINC02757 locus, rs12081541 in the CCDST-LCE5A region, rs60242841 in LINC00299, rs9565267 in RN7SL571P-KCTD12, and rs151041509 in LINC02512. Many of these variants are located in or near long non-coding RNA genes (LINC02757, LINC00299, LINC02512) or genes involved in cellular processes, suggesting their influence on gene expression or protein function. For example, LCE5A is part of the late cornified envelope gene cluster, which is important for skin barrier integrity, similar to FLG, a known major risk factor for eczema. [2] While specific mechanisms for each of these variants are still being elucidated, their identification in genetic studies highlights the multifaceted nature of atopic march susceptibility, involving diverse biological pathways that collectively contribute to the progression of allergic diseases. [1]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs2155219 | EMSY - LINC02757 | allergic sensitization measurement atopic march ulcerative colitis seasonal allergic rhinitis asthma |
| rs12081541 | CCDST - LCE5A | atopic march |
| rs479844 | AP5B1 - OVOL1 | atopic march atopic eczema asthma serum IgG glycosylation measurement childhood onset asthma |
| rs993226 | RPL6P25 - SLC6A15 | atopic march |
| rs9357733 | EFHC1 | atopic march |
| rs17690965 | KIF3A | atopic march |
| rs10445308 | IKZF3 | atopic march asthma, cardiovascular disease asthma |
| rs60242841 | LINC00299 | atopic march |
| rs9565267 | RN7SL571P - KCTD12 | atopic march |
| rs151041509 | LINC02512 | atopic march |
Conceptual Framework of the Atopic March
The atopic march describes a characteristic progression of atopic diseases, typically beginning in early childhood. The most common manifestation involves eczema (atopic dermatitis) appearing first, followed by the development of asthma later in childhood. [2] Epidemiological studies strongly support this concept, demonstrating a significantly increased risk of asthma in children with early eczema. [2] For instance, a large study on allergic disease progression found that 60.7% of allergic children developed eczema initially, and 86% of all children with eczema experienced it as their first allergic condition, highlighting its role as a common initiating factor in the sequence of allergic manifestations. [2]
This trajectory suggests a potential causal relationship between early eczema and subsequent asthma development, implying that interventions targeting skin integrity in infancy could potentially prevent or arrest the atopic march in a subset of patients. [2] Beyond eczema and asthma, the atopic march can encompass other allergic conditions, including IgE-mediated food allergy (IgE-FA) and allergic rhinitis (AR), which may manifest as subsequent allergic events following atopic dermatitis. [1] Research also explores distinct "allergic march trajectories" and potential differences in these progressions across various populations. [1]
Clinical and Research Definitions of Atopic March Components
Defining the atopic march and its constituent conditions relies on specific diagnostic and measurement criteria. Atopic dermatitis (AD) is clinically diagnosed by pediatric allergists, often based on established guidelines such as the revised Hanifin and Rajka criteria [11] or the UK diagnostic criteria. [10] Severity of AD is commonly quantified using indices like the Severity SCORing Atopic Dermatitis (SCORAD) index, with moderate to severe AD typically defined by a SCORAD score of 30 or greater in research settings. [11] Allergic sensitization, a key component of atopy, is identified by specific IgE levels greater than 0.7 kUA/l to common food or airborne allergens, including egg white, milk, peanut, wheat, Dermatophagoides pteronyssinus, Dermatophagoides farina, and Alternaria. [11]
For research purposes, particularly in genome-wide association studies (GWAS), the atopic march is often operationally defined as the presence of early-onset eczema (up to 3 years of age) combined with childhood asthma (up to 16 years of age). [2] Cases of atopic dermatitis for these studies are often identified as individuals who have "ever had atopic dermatitis," with a preference for doctor-diagnosed cases, while controls are defined as those who have never experienced the condition. [12] The presence or absence of allergic conditions like AD, IgE-FA, asthma, and AR can also be ascertained using International Classification of Diseases (ICD) diagnosis codes, allergen information, and medication prescriptions, requiring diagnosis codes on two separate care visits for inclusion in disease cohorts. [1]
Related Terminology and Immunological Context
The terminology surrounding the atopic march involves several key concepts and related conditions. "Eczema" and "atopic dermatitis" are often used interchangeably, with standardized terminologies recognizing these conditions through identifiers such as EFO_0000274 or HP_0000964 for eczema. [4] Similarly, "asthma" is recognized with MONDO_0004979 and "allergic disease" with MONDO_0005271. [4] Asthma itself can be classified into subtypes, such as "atopic asthma," characterized by high eosinophils, mast cells, and T lymphocytes, contrasting with "non-atopic asthma," which typically displays high neutrophils and mast cells. [13]
Immunologically, the shift in immune response is significant. For example, in obese asthmatics, there is a reported shift from a T helper (Th) 2 immunological profile, which is typical of atopy, to a Th150 profile. [13] This change can lead to airway inflammation driven predominantly by neutrophils, offering a partial explanation for the stronger association of obesity with later-onset and non-atopic asthma. [13] Understanding these distinct immunological profiles and their associated inflammatory patterns is crucial for deciphering the molecular determinants of the atopic march and potentially identifying novel therapeutic approaches to prevent or halt its progression. [2]
Characteristic Progression and Early Manifestations
The atopic march typically presents as a sequential progression of allergic diseases, most commonly beginning with early-onset eczema, also known as atopic dermatitis (AD), followed by the development of childhood asthma. [2] Eczema often manifests in infancy, with studies indicating that it is the initial allergic condition in the vast majority of children who experience it, making subsequent development of asthma or allergic rhinitis less common. [2] This early appearance of eczema is a significant prognostic indicator, as it confers a substantially increased risk for developing asthma later in childhood, with one cohort study reporting a 4.3-fold increase in asthma risk. [2] Beyond eczema and asthma, the march can also involve other allergic manifestations such as IgE-mediated food allergy and allergic rhinitis, contributing to a broader spectrum of allergic trajectories. [1]
Clinical Phenotypes and Assessment Methods
The clinical presentation of atopic march components can vary in severity and specific phenotypes. Atopic dermatitis, a foundational element, is typically diagnosed by experienced dermatologists or pediatricians using established criteria, such as the UK diagnostic criteria. [10] Cases often involve moderate-to-severe disease with onset in childhood. [10] Assessment methods for allergic conditions include objective measures like serum specific IgE levels to common allergens and total serum IgE levels, which help characterize the allergic sensitization. [11] Longitudinal cohort studies, such as the Avon Longitudinal Study of Parents and Children (ALSPAC), are crucial for tracking the development and progression of eczema and asthma throughout childhood, providing valuable data on the natural history of the atopic march. [2] Advanced analytical approaches, including unsupervised cluster analysis, are also employed to identify distinct allergic trajectories and patterns of disease development. [1]
Heterogeneity and Genetic Correlates
The atopic march exhibits considerable heterogeneity, with variations in presentation patterns across individuals and populations. Global studies highlight variations in the prevalence of eczema symptoms in children, suggesting inter-individual and geographical diversity in allergic manifestations. [14] Phenotypic diversity is further observed in the specific sequence of allergic diseases, with different trajectories identified, such as AD preceding IgE-mediated food allergy, asthma, or allergic rhinitis. [1] Genetic analyses reveal a largely shared genetic architecture across atopic diseases, with many atopic dermatitis loci overlapping with atopic march susceptibility loci. [4] However, specific genetic loci, such as IKZF3 on chromosome 17, may show stronger associations with asthma alone compared to the atopic march, while other novel loci like rs9357733 and rs993226 confer risk for the atopic march but not for eczema alone or asthma alone, underscoring distinct genetic contributions to the combined phenotype. [2]
Genetic Predisposition and Risk Loci
The development of the atopic march is significantly influenced by inherited genetic factors, reflecting a complex interplay of multiple susceptibility loci. Genome-wide association studies (GWAS) have identified several single nucleotide polymorphisms (SNPs) contributing to risk, highlighting the polygenic nature of this condition. For instance, a meta-analysis identified seven susceptibility loci at genome-wide significance, including two novel variants, rs9357733 and rs993226, which specifically confer risk for the atopic march. [2] Additional confirmed loci include rs17690965 near CRNN/LCE5A, rs479844 in AP5B1/OVOL1, and rs2155219 within C11orf30/LRRC32, alongside a region around rs10445308 in an intron of IKZF3. [2]
Specific genetic variants, such as the FLG-null mutations R501X and 2282del4, are also major contributors, particularly in European populations, underscoring the role of skin barrier dysfunction in the initial stages. Beyond these, other loci like IL6R, IL1RL1/IL18R1, RAD50, and the human leukocyte antigen (HLA) region have been replicated as associated with atopic diseases, collectively shaping an individual's predisposition to developing the sequential progression of atopic conditions. [2] The genetic signal for atopic dermatitis, a key initiator, shows enrichment in immune cells, especially T-cells, indicating a fundamental role for immune system regulation in the underlying genetic architecture. [4]
Shared Genetic Architecture and Disease Progression
A significant aspect of the atopic march's etiology lies in the shared genetic architecture among its constituent atopic diseases, such as eczema, asthma, and allergic rhinitis. Research indicates that most identified genetic loci for atopic dermatitis overlap with those for other atopic march phenotypes, supporting a common genetic basis that facilitates the progression from one condition to the next. [4] This genetic overlap suggests that individuals carrying these susceptibility variants are predisposed to a broader spectrum of allergic manifestations rather than isolated conditions.
Specific loci, such as those within OVOL1 and C11orf30/LRRC32, have demonstrated an effect on the progression from eczema to asthma, illustrating how certain genetic factors may drive the sequential development characteristic of the atopic march. [2] While some loci, like IKZF3, show a stronger association with asthma alone, others, including the newly identified atopic march-specific loci (rs9357733 and rs993226), do not exhibit a distinct effect on eczema or asthma in isolation, suggesting their unique role in the combined phenotype. [2] This intricate genetic landscape, with both shared and specific risk variants, underlies the complex trajectory.
Gene-Environment Interactions and Early Life Factors
The development of the atopic march is not solely determined by genetics but also involves crucial interactions between an individual's genetic predisposition and various environmental factors, especially during early life. Although specific environmental triggers are not extensively detailed in all studies, the existence of gene-environment interactions is recognized as a significant component of the genetic architecture of atopic dermatitis and related conditions. [15] These interactions imply that genetic vulnerabilities can be modulated or triggered by external influences, leading to the manifestation of atopic diseases.
Early life experiences play a critical role, as evidenced by studies utilizing birth cohorts that track the longitudinal development of eczema and asthma throughout childhood. [2] Such research highlights that the timing and nature of exposures during infancy and early childhood can shape the trajectory of atopic disease progression in genetically susceptible individuals. Furthermore, observed global variations in the prevalence of eczema symptoms suggest that geographic and socioeconomic factors, which encompass diverse environmental exposures and lifestyles, may contribute to the complex etiology. [14] The interplay between inherited tendencies and environmental exposures during critical developmental windows is thus fundamental to understanding the onset and progression of the atopic march.
Biological Background
The atopic march describes the typical progression of allergic diseases, often starting with early-onset eczema, followed by food allergy, asthma, and allergic rhinitis. [16] This sequential development underscores a complex interplay of genetic predispositions, immune system dysregulation, and environmental factors. Research highlights that early eczema significantly increases the risk of developing asthma, suggesting that understanding the underlying biological mechanisms is crucial for potential preventative strategies. [16]
Genetic Architecture and Susceptibility Loci
The atopic march is significantly influenced by an individual's genetic makeup, with numerous susceptibility loci identified through genome-wide association studies (GWAS). A meta-analysis identified seven such loci at genome-wide significance, including two novel variants, rs9357733 and rs993226, associated with the atopic march. [16] Other notable loci include regions near FLG (rs12081541), CRNN/LCE5A (rs17690965), AP5B1/OVOL1 (rs479844), C11orf30/LRRC32 (rs2155219), SLC6A15/TMTC2 (rs993226), and IKZF3 (rs10445308). [16] The substantial overlap between atopic dermatitis (AD) loci and atopic march loci indicates a largely shared genetic architecture across these allergic conditions, emphasizing common underlying biological pathways. [17]
These genetic variants can influence gene expression patterns, as demonstrated by the evaluation of novel atopic march loci in lymphoblastoid cell lines and the integration of multi-omic quantitative trait loci (QTLs) to prioritize disease-causal genes. [16] For instance, the IKZF3 gene, located on chromosome 17, is an intron-located DNA-binding protein previously linked to childhood asthma and self-reported allergy. [16] Furthermore, specific genetic polymorphisms have been associated with distinct allergic march trajectories, such as rs60242841 with progression from AD to asthma. [1]
Immune System Dysregulation and Cytokine Signaling
Immune cells, particularly T-cells, are critically involved in the genetic signals of atopic dermatitis and, by extension, the atopic march. [17] Genetic loci identified in atopic diseases often highlight genes involved in immune regulation and inflammatory responses. Key biomolecules and pathways implicated include those related to IL-6 and IL-22 signaling, with genes such as IL6ST, IL22RA2, and SOCS3 identified as prioritized candidates. [17] These genes encode receptors and negative regulators of cytokine signaling, suggesting that disruptions in these pathways contribute to the chronic inflammation characteristic of atopic conditions.
Other immune-related genes, such as ITK and BATF, have also been identified at novel atopic dermatitis loci, further supporting the central role of immune cell function in the pathophysiology of the atopic march. [17] The involvement of such pathways underscores how aberrant immune responses, often initiated in the skin, can propagate systemically, leading to the development of subsequent allergic manifestations. The human leukocyte antigen (HLA) region, known for its role in immune recognition, is also a susceptibility locus associated with both atopic dermatitis and asthma. [16]
Skin Barrier Dysfunction and Epithelial Biology
A compromised skin barrier is a foundational element in the initiation of the atopic march, with eczema frequently being the first allergic condition to manifest. [16] Genes involved in maintaining skin integrity play a significant role, notably FLG (filaggrin), where mutations like R501X and 2282del4 are common in individuals of European descent. [16] Filaggrin is a structural protein essential for the formation of the epidermal barrier, and its dysfunction can lead to increased transepidermal water loss and enhanced penetration of allergens, thereby sensitizing the immune system.
Other loci such as CRNN/LCE5A and C11orf30/LRRC32 are also associated with eczema and the atopic march, further highlighting the importance of epithelial function. [16] The initial breach in the skin barrier allows allergens to enter the body, triggering immune responses that can then prime the individual for subsequent allergic reactions in other organ systems, such as the respiratory tract. This "outside-in" hypothesis suggests that maintaining skin integrity early in infancy could be a crucial strategy to prevent the progression of the atopic march. [16]
Pathophysiological Progression and Systemic Interconnections
The atopic march describes a specific pathophysiological sequence where early manifestations like eczema can drive the development of later allergic diseases. Epidemiological studies show that early eczema can increase the risk of asthma by 4.3-fold, suggesting a causal relationship between these conditions. [16] The progression from skin-centric inflammation to systemic allergic responses involves complex tissue interactions and systemic consequences, where immune sensitization initiated in the skin predisposes individuals to allergic reactions in the lungs or elsewhere.
While some genetic loci, like FLG and C11orf30/LRRC32, show a stronger association with eczema and the atopic march than with asthma alone, other loci, such as IKZF3, exhibit a more pronounced effect on asthma. [16] This differential impact of genetic variants on specific atopic phenotypes underscores the intricate and sometimes distinct molecular pathways involved in the various stages of the atopic march. Understanding these interconnected processes and the specific genetic drivers for each stage is vital for developing targeted therapeutic and preventative strategies.
Immune Cell Signaling and Inflammatory Responses
Immune cells, particularly T-cells, are centrally involved in the genetic signals associated with atopic dermatitis, a key component of the atopic march. [4] Dysregulation in specific signaling cascades, such as the IL-6 and IL-22 pathways, plays a significant role, with genes like IL6ST, IL22RA2, and SOCS3 highlighted as prioritized candidates. These genes are integral to receptor activation and subsequent intracellular signaling cascades that modulate immune responses and inflammation. Furthermore, ITK and BATF are identified as candidate genes at novel loci, suggesting their involvement in T-cell differentiation and effector functions that drive the allergic inflammatory trajectory.
Epidermal Barrier Function and Genetic Regulation
Genetic variations influencing epidermal barrier function are critical mechanisms in the atopic march, particularly in the initiation of eczema. Loci such as FLG (Filaggrin), CRNN/LCE5A, OVOL1, and C11orf30/LRRC32 are strongly associated with eczema and subsequent progression to other atopic diseases. [2] These genes are involved in maintaining skin integrity, and their dysregulation, often due to specific genetic polymorphisms, leads to impaired barrier function. This impaired barrier allows increased allergen penetration and initiates inflammatory responses, acting as a foundational step in the allergic cascade.
Network Interactions and Shared Genetic Architecture
The atopic march involves a complex interplay of genetic factors, demonstrating a largely shared genetic architecture across atopic diseases, where many atopic dermatitis loci overlap with general atopic march susceptibility regions. [4] This systems-level integration highlights significant pathway crosstalk and network interactions among immune regulatory genes. For instance, loci like IL6R, IL1RL1/IL18R1, RAD50, and the HLA region, along with C11orf30, are consistently associated with both atopic dermatitis and other atopic traits, underscoring their broad impact on systemic immune regulation. [2] Such shared genetic underpinnings suggest a hierarchical regulation of immune responses that contribute to the emergent properties of multi-organ atopy.
Genetic Loci and Disease Trajectory
Genome-wide association studies have identified several susceptibility loci that significantly influence the trajectory of the atopic march, linking early-onset eczema to subsequent asthma and other allergic manifestations. [2] Key genetic variants such as rs12081541 near CRNN/LCE5A (FLG), rs17690965 and rs479844 near AP5B1/OVOL1, rs2155219 in C11orf30/LRRC32, rs993226 in SLC6A15/TMTC2, and rs10445308 in IKZF3 are consistently associated with the atopic march. [2] These loci mediate pathway dysregulation that drives disease progression, with some, like C11orf30/LRRC32, specifically demonstrating an effect on the transition from eczema to asthma. [2] Understanding these specific genetic contributions provides critical insights into potential therapeutic targets to arrest or prevent the progression of atopic diseases.
Prognostic Value and Risk Stratification
The concept of the atopic march holds significant prognostic value, as early-onset atopic dermatitis (AD) is a strong predictor for the subsequent development of other allergic conditions, particularly asthma. Research, including large population-based birth cohorts like the Avon Longitudinal Study of Parents and Children (ALSPAC), demonstrates that early eczema increases the risk of asthma by 4.3-fold. [2] This progression often follows a distinct trajectory where eczema is the first allergic manifestation in a majority of affected children, indicating that developing eczema after asthma or allergic rhinitis is uncommon. [2] Identifying individuals at high risk for progressing through the atopic march allows for targeted risk stratification and potentially earlier interventions.
Beyond the initial diagnosis of AD, specific demographic characteristics and genetic markers can further refine risk assessment. Studies employing unsupervised cluster analysis and supervised decision tree modeling have identified associations between self-identified "Black" race and progression from AD to asthma, "Asian or Pacific Islander" race with progression from AD to IgE-mediated food allergy (IgE-FA), and "White" race with progression from AD to allergic rhinitis (AR). [1] These insights into distinct allergic trajectories and their demographic and genetic underpinnings are crucial for personalized medicine approaches, enabling clinicians to identify individuals who may benefit most from early monitoring or preventive strategies based on their specific risk factors.
Genetic Markers and Diagnostic Insights
Genetic studies have revealed specific susceptibility loci that contribute to the development and progression of the atopic march, offering valuable diagnostic utility and insights into disease mechanisms. A meta-analysis identified seven genome-wide significant loci associated with the atopic march, including two novel variants, rs9357733 and rs993226, which specifically conferred risk for the combined atopic march phenotype but not for eczema alone or asthma alone. [2] Several loci initially linked to eczema, such as FLG, IL4/KIF3A, OVOL1, and C11orf30/LRRC32, show a stronger association with the atopic march compared to eczema alone, with C11orf30/LRRC32 previously implicated in disease progression from eczema to asthma. [2] Conversely, the IKZF3 locus, primarily associated with asthma, exhibits a stronger effect on asthma than on the atopic march. [2]
The identification of these genetic markers supports a largely shared genetic architecture across atopic diseases, as many atopic dermatitis loci overlap with those found in atopic march genome-wide association studies. [4] Furthermore, specific risk loci for progression from AD to asthma, such as rs60242841, have been identified, being more common in individuals of African ancestry. [1] Similarly, loci associated with progression from AD to AR, including rs9565267 and rs151041509, are more prevalent in European ancestry individuals. [1] Understanding these genetic predispositions can aid in early risk assessment, guiding diagnostic efforts and informing discussions about potential future allergic conditions based on an individual's genetic profile and ancestral background.
Therapeutic and Preventive Strategies
The understanding of the atopic march has significant implications for developing targeted therapeutic and preventive strategies aimed at interrupting or mitigating the progression of allergic diseases. The causal relationship between early eczema and subsequent asthma suggests that modulating skin integrity in infancy could be an effective approach to prevent not only eczema but also the atopic march in a subset of patients. [2] Early interventions, such as skin emollient therapy in neonates, have shown promising results in preventing eczema. [2] However, the long-term impact of such therapies on preventing asthma in these children still requires further demonstration. [2]
Deciphering the molecular determinants underlying the atopic march is critical for identifying novel therapeutic targets and approaches. By understanding the genetic and mechanistic pathways involved in the progression from one allergic condition to another, researchers aim to develop interventions that can prevent or at least arrest the atopic march. [2] This could involve therapies that modulate immune responses, strengthen skin barrier function, or address specific genetic predispositions, ultimately leading to more effective prevention and management strategies for this complex sequence of allergic disorders.
Frequently Asked Questions About Atopic March
These questions address the most important and specific aspects of atopic march based on current genetic research.
1. My older child had eczema. Will my newborn definitely get all the allergies too?
Not necessarily. While there's a genetic predisposition, the progression isn't guaranteed. Some individuals skip certain allergic manifestations or halt the progression entirely. About 20-30% of infants with eczema follow the full trajectory, so there's variability even with a family history.
2. My baby's eczema is really bad. Does that mean they'll get severe asthma later?
Yes, severe early-onset atopic dermatitis is a significant risk factor. Research shows that more severe eczema in infancy is often associated with a higher likelihood of developing food sensitization and subsequent allergic conditions like asthma. This link is well-established, highlighting the importance of managing eczema early.
3. If I keep my child's eczema under control, can I stop them from getting asthma?
Managing eczema is crucial, especially since skin barrier dysfunction is a key factor. While early intervention can help, genetics play a strong role in this progression. For example, variations in the filaggrin gene (FLG) are a major predisposing factor for eczema and related allergies, meaning some underlying susceptibility might still lead to asthma even with good eczema control.
4. Why did my cousin only get eczema, but I got eczema and asthma?
There's a complex interplay of genetics and environment that explains these differences. While a shared genetic architecture exists across atopic diseases, specific genetic variations you inherited, potentially in genes like EFHC1 or others, might predispose you to a broader range of allergic conditions compared to your cousin. Environmental exposures also play a role in how these genes manifest.
5. Can a special skin cream prevent my child from developing food allergies?
There's a growing understanding that improving the skin barrier might help. Loss-of-function variants in genes like filaggrin (FLG) weaken the skin barrier, making individuals more prone to eczema and subsequent allergies. While research is ongoing, strengthening the skin barrier through emollients could potentially reduce allergen exposure through the skin and impact the risk of developing food allergies.
6. Should I get a special test to see if my child is at risk for more allergies?
Identifying at-risk individuals is a key clinical goal. While specific genetic tests for "atopic march risk" aren't standard yet, understanding your child's eczema severity and family history can help. Researchers have identified several genetic markers associated with this progression, and future tests might help personalize risk assessment and guide early interventions.
7. I had eczema as a kid but nothing else. Does that mean I'm safe now?
It's likely you've halted the progression. While some individuals experience a full march, others only manifest one or two conditions. The pattern describes a progression typically observed later in childhood, so if you only had eczema and didn't develop other allergies, you are probably not going to develop them now due to the atopic march.
8. Does my family's background make my child more likely to have this march of allergies?
Yes, genetic predisposition is a significant factor. Your family's background can influence the genetic variants your child inherits, which in turn can affect their susceptibility to the atopic march. Health disparities related to allergic manifestations have been observed, underscoring how genetics and environmental factors vary across populations.
9. Is there anything I can do at home to stop my child's eczema from turning into asthma?
Early and consistent management of eczema is important, as it's often the first step in the march. This includes good skin care to maintain the skin barrier. While genetics play a substantial role, minimizing exposure to allergens and irritants can also be part of a comprehensive strategy to potentially mitigate the progression of allergic diseases.
10. My child has eczema and now a food allergy. Is it guaranteed they'll get asthma too?
It's not guaranteed, but your child is at a significantly higher risk. The progression from early onset atopic dermatitis to food sensitization and then to respiratory allergies like asthma and allergic rhinitis is a common pattern in the atopic march. However, individual variations exist, and some children may not develop every condition in the sequence.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Gabryszewski, S. J. "Unsupervised Modeling and Genome-Wide Association Identify Novel Features of Allergic March Trajectories." J Allergy Clin Immunol, vol. 146, no. 3, 2020, pp. 581-591.e9.
[2] Marenholz, I. et al. "Meta-analysis identifies seven susceptibility loci involved in the atopic march." Nat Commun, 2015, PMID: 26542096.
[3] Drislane, C., and A. D. Irvine. "The role of filaggrin in atopic dermatitis and allergic disease." Annals of Allergy, Asthma & Immunology, vol. 124, no. 1, 2020, pp. 36–43.
[4] Oliva, M., et al. "Integration of GWAS, QTLs and keratinocyte functional assays reveals molecular mechanisms of atopic dermatitis." Nat Commun, vol. 14, no. 1, 2023, p. 40164604.
[5] Flohr, C., et al. "Atopic dermatitis and disease severity are the main risk factors for food sensitization in exclusively breastfed infants." J Invest Dermatol, vol. 134, no. 2, 2014, pp. 345–50.
[6] Hill, D. A., et al. "Eosinophilic esophagitis is a late manifestation of the allergic march." J Allergy Clin Immunol Pract, vol. 6, no. 5, 2018, pp. 1599-1606.e1.
[7] Belgrave, D. C., et al. "Atopic dermatitis and respiratory allergy: What is the link." Curr Dermatol Rep, vol. 4, no. 4, 2015, pp. 221–27.
[8] Drucker, A. M., et al. "The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association." J Invest Dermatol, vol. 137, no. 1, 2017, pp. 26–30.
[9] Ishigaki, K., et al. "Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases." Nat Genet, 2020. PMID: 32514122.
[10] Weidinger, S. et al. "A genome-wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis." Hum Mol Genet, 2013, PMID: 23886662.
[11] Kim, K. W. et al. "Genome-wide association study of recalcitrant atopic dermatitis in Korean children." J Allergy Clin Immunol, 2015, PMID: 25935106.
[12] Budu-Aggrey, A. et al. "European and multi-ancestry genome-wide association meta-analysis of atopic dermatitis highlights importance of systemic immune regulation." Nat Commun, 2023, PMID: 37794016.
[13] Zhu, Z. et al. "Shared Genetic and Experimental Links between Obesity-Related Traits and Asthma Subtypes in UK Biobank." J Allergy Clin Immunol, 2019, PMID: 31669095.
[14] Gautam Y, et al. "Joint genotype and ancestry analysis identify novel loci associated with atopic dermatitis in African American population." HGG Adv, 2023.
[15] Buil A, et al. "Gene-gene and gene-environment interactions detected by transcriptome sequence analysis in twins." Nat Genet, 2015.
[16] Marenholz I, et al. "Meta-analysis identifies seven susceptibility loci involved in the atopic march." Nat Commun, 2016.
[17] Oliva M, et al. "Integration of GWAS, QTLs and keratinocyte functional assays reveals molecular mechanisms of atopic dermatitis." Nat Commun, 2024.